On November 1, 2021 Patrys has reported a $7.8 million capital raising via a Placement and fully underwritten Rights Issue (Press release, Patrys, NOV 1, 2021, View Source [SID1234605548]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These funds will significantly strengthen Patrys’ balance sheet, providing for:

Initiation of a formal development program for PAT-DX3, Patrys’ full-sized IgG deoxymab antibody, that is expected to provide Patrys with additional development and partnering opportunities;
Development of a manufacturing process to provide clinical‑grade PAT-DX3 at commercial scale including establishing a stable, high-yielding producer cell line.
Further R&D studies including use of deoxymabs for targeted delivery to support potential inhouse and partnered programs for antibody drug conjugates (ADCs);
Expansion of the Company’s business development activities, working capital, corporate activities, and offer costs.
Territory Funds Management has strongly supported this capital raise and we are pleased to offer existing shareholders an opportunity to invest in this exciting growth opportunity too via the fully underwritten 1:12 Rights Issue.